Relationship between EGFR gene mutation and local metastasis of resectable lung adenocarcinoma

Yunqiang Nie, Wei Gao, Na Li, Wenjun Chen, Hui Wang, Cuiyun Li, Haiyan Zhang, Ping Han, Yingmei Zhang, Xin Lv, Xinyi Xu and Hongyan Liu

Abstract

Background: Resectable lung adenocarcinoma is dominated by peripheral distribution, and surgical resection is the main treatment protocol. However, high recurrence rate remains after surgery. Lung adenocarcinoma with epidermal growth factor receptor (EGFR) mutation has strong invasion ability, but the effects of this mutation on local invasion in early lung adenocarcinoma have been rarely studied. This study aimed to assess the effects of EGFR mutation on local invasion in resectable lung adenocarcinoma.

Methods: A retrospective analysis of 103 patients clinically diagnosed with peripheral lung adenocarcinoma was included. They underwent preoperative bronchoscopy, which indicated grades 2 or 3 bronchial involvement (lumen of the lobe or segment). The associations of EGFR mutation with pleural invasion, endobronchial metastasis, and lymph node metastasis were analyzed according to pathologies of pleural invasion and lymph node metastasis, as well as EGFR gene mutation detected by postoperative pathological specimens. Statistical analyses were performed by unpaired Chi-square test using the SPSS16.0 software.

Results: In patients with EGFR mutation, pleural invasion, endobronchial metastasis, and lymph node metastasis rates were 62.5, 39.1, and 34.4%, respectively, indicating statistically significant differences ($p = 0.003$). Meanwhile, the pleural invasion rate in patients with wild-type EGFR was 43.6%, significantly reduced compared with patients with mutated EGFR (62.5%; $p = 0.018$). In addition, the endobronchial metastasis rate in patients with wild-type EGFR was 17.9%, significantly lower than in patients with EGFR mutation (39.1%; $p = 0.005$). However, lymph node metastasis rates were similar between EGFR mutated and wild-type patients (34.4 vs 25.6%, respectively, $p > 0.05$).

Conclusions: Early resectable lung adenocarcinoma patients with EGFR mutation showed a higher rate of local invasion compared with those harboring wild-type EGFR. This finding provides a basis for improved therapy.

Trial registration: This study was supported by Project of Medical and Health Science Technology in Shandong Province (2015WS0376)

Keywords: Lung adenocarcinoma, Endobronchial metastasis, Bronchial grade, Bronchoscopy, EGFR

Background

Computed tomography (CT) diagnosis rate for early peripheral lung adenocarcinoma is increasingly higher, and surgical resection of lung segment and lobe is more popular. However, high recurrence rate remains after surgery. Selection of the surgical margin is one of the key factors affecting recurrence. The EGFR gene affects the invasion capability of lung adenocarcinoma. However, how EGFR mutation helps early lung adenocarcinoma invade local structures that has been rarely studied, and it is not known whether it can provide a basis for treatment in early lung adenocarcinoma. In this study, bronchial invasion was accurately assessed by preoperative bronchoscopy, combined with postoperative pathologies of pleural and lymph node metastases as well as EGFR gene mutation assays, to further elucidate local invasion in early...
Methods

Patients
A retrospective analysis of 103 outpatients or inpatients treated at Linyi People’s Hospital, between January 2011 and August 2015, were selected. They presented with sputum, cough, chest pain, fever or blood sputum, and were pathologically diagnosed with lung adenocarcinoma postoperatively. They included 50 men (59.38 ± 10.038 years old), and 53 women (57.73 ± 11.706 years old). Among them, there were 30 smokers, including 25 men and 5 women. The patients underwent high-resolution CT (HRCT) examinations, and lesions were found in the peripheral lung. Patients were tolerable to bronchoscopy and surgery.

Examination methods

1) All patients underwent 64-sliced CT (Light Speed VCT 64, GE Company Fairfield USA) plain and enhanced scans, with layer thickness and interval of 0.625 mm. The CT scanning ranged from the superior aperture of thorax to the costophrenic angle. Plain scans were first performed, followed by bolus injection of contrast agent with a high-pressure syringe (iopromide 300, 300 mgI/ml; flow rate, 3 ml/s; total amount, 80 ml; cubital vein injection). Enhanced scans were conducted in delayed stage (30 s after venous stage). Three-dimensional reconstruction was performed if necessary; the horizontal plan was considered the routine layer. Peripheral or central lung cancer was initially determined. All patients underwent bronchoscopic examination (BF260, Olympus, Tokyo, Japan) and grades 2 or 3 (lumen of the lobe or segment (2 or 3 grade invasive bronchus) invaded by peripheral lung adenocarcinoma, or other bronchial lumens were invaded beyond the lobe containing the tumor. Features of metastasis bronchus: mucosal hyperemia and edema, infiltration change, polypoid change, etc.; meanwhile, lung adenocarcinoma was confirmed by endoscopic biopsy and pathology. All patients underwent a bronchoscopic examination, performed by expert pulmonologists using an Olympus EVIS bronchovideoscope BF260 (Olympus, Tokyo, Japan). If no significant endobronchial lesions were found in the most distal bronchi by bronchoscopy, the patient was considered to have no endobronchial metastasis. However, if a tumor mass or infiltration was visible by bronchoscopy, the patient was considered to have endobronchial metastasis. Bronchial grading was defined as follows: tracheal, 0; right and left main bronchus, 1; lobar bronchus, 2; segmental bronchus, 3.

2) EGFR gene detection:
Postoperative pathological sections were used to assess 18, 19, 20, and 21 exon mutation on ARMS-PCR (scorpion amplification refractory mutation system) [2] with Gene mutation detection kit purchased from Amoy Diagnostics Co. Ltd. (Xiamen, China).

Evaluation criteria
According to the pathological results, pleural invasion was defined to extend beyond the elastic pleural layer, and lymph node metastasis was diagnosed by postoperative lymph node pathology. Endobronchial metastasis referred to lumen of the lobe or segment (2 or 3 grade bronchus) invaded by peripheral lung adenocarcinoma, or other bronchial lumens were invaded beyond the lobe containing the tumor. Features of metastasis bronchus: mucosal hyperemia and edema, infiltration change, polypoid change, etc.; meanwhile, lung adenocarcinoma was confirmed by endoscopic biopsy and pathology. All patients underwent a bronchoscopic examination, performed by expert pulmonologists using an Olympus EVIS bronchovideoscope BF260 (Olympus, Tokyo, Japan). If no significant endobronchial lesions were found in the most distal bronchi by bronchoscopy, the patient was considered to have no endobronchial metastasis. However, if a tumor mass or infiltration was visible by bronchoscopy, the patient was considered to have endobronchial metastasis. Bronchial grading was defined as follows: tracheal, 0; right and left main bronchus, 1; lobar bronchus, 2; segmental bronchus, 3.

Surgical procedure
In the VATS procedure, all patients underwent general anesthesia with double lumen endotracheal intubation and single lung ventilation. The patient was placed in the lateral decubitus position. Thoracoscopic lobectomy was performed through three or four incisions. We placed a thoracoscope in the 7th or 8th intercostal space in the middle or anterior axillary line. The main operating port of incision was located at the anterior axillary line in the 4th or 5th intercostal space, with a length of about 3 cm; the port just facing the lung hilus was the best. A 1.5 cm auxiliary operating port was placed in the auscultation triangle. The lung and pleural space were carefully inspected for unexpected metastatic disease. According to the various fissure situations, the management sequence of pulmonary arteries, veins, and bronchia was different. Pulmonary artery, vein, bronchus, and fissure were divided using an Endoscopic Linear Cutter. The pulmonary artery with smaller diameter (<7 cm) was ligated using Hem-o-lok. Lymph node dissection was performed by standard procedure, removing all accessible Hilir and mediastinal lymph nodes, including levels L2–L4, and L7–L11 on the right side, and levels L4–L11 on the left side, according to the American Thoracic Society classification.

For thoracotomy, a posterolateral skin incision ranging in length from 20 to 25 cm was made. The latissimus dorsi and serratus anterior muscles were dissected along the fifth intercostal space. Thoracotomy was performed at the fifth intercostal space, with
the fifth rib sectioned at the costovertebral angle. A standard rib retractor was inserted. All resections were performed in a conventional manner. Hilar and mediastinal lymph node dissection was performed in all patients, and the extent of mediastinal lymph node dissection was the same as in the VATS group. One chest tube was placed at the posterior aspect of the chest cavity.

Statistical analysis
Statistical analyses were performed by unpaired Chi-square test using the SPSS16.0 software. \( p < 0.05 \) was considered statistically significant.

Results
According to postoperative pathological TNM staging, there were 52, 24, and 27 stages I, II, and IIIA cases, respectively. Patients with EGFR mutation represented 62.14% (64/103); 37.86% (39/103) harbored wild-type exon.

Local invasion
A total of 60 cases with pleural invasion were found, including 43 and 17 patients with mutated and wild-type EGFR, respectively; there were 32 cases of lymph node metastasis, including 22 and 10 patients with mutated and wild-type EGFR, respectively. A total of 32 cases of endobronchial metastasis were found, including 25 with mutated EGFR and 7 with wild-type gene.

Among the 64 patients with EGFR mutation, pleural invasion, endobronchial metastasis, and lymph node metastasis rates were 62.5% (43/64), 39.1% (25/64), and 34.4% (22/64), respectively, showing statistically significant differences \( (p = 0.003) \). For the 39 wild-type patients, pleural invasion, endobronchial metastasis, and lymph node metastasis rates were 43.6% (17/39), 17.9% (7/39), and 25.6% (10/39), respectively, indicating statistically significant differences among the three groups \( (p = 0.038) \). Interestingly, pleural invasion \( (p = 0.018) \) and endobronchial metastasis \( (p = 0.005) \) rates in patients with EGFR mutation were significantly higher compared with those obtained for individuals harboring wild-type EGFR. However, the difference in lymph node metastasis rates between both groups was not statistically significant \( (p > 0.05) \) (Tables 1 and 2) (Fig. 1).

Relationship between EGFR gene mutation and pathological staging
p-stage I incidence was highest (54.7%, 35/64) in patients with EGFR mutations, followed by p-stage IIIA (28.1%, 18/64), and p-stage II (17.2%, 11/64), indicating statistically significant differences among the three stages \( (p < 0.001) \). For patients without EGFR mutation, p-stage I, p-stage II, and p-stage IIIA incidence rates were 43.6, 33.3, and 23.1%, respectively, and the differences were not statistically significant \( (p = 0.158) \) (Table 3).

Surgical methods
Three patients underwent sleeved lobectomy, including 2 and 1 with mutated and wild-type EGFR, respectively; 8 patients had pulmonary wedge resection, including 4 in each group; 3 patients underwent segmentectomy, including 1 and 2 with mutated and wild-type EGFR, respectively; 85 patients underwent lobectomy, including 31 harboring wild-type EGFR and 54 with mutated gene; 4 patients underwent two lobe combination resection, including 3 and 1 with mutated and wild-type EGFR. 4 patients (3 patients with pulmonary wedge resection and 1 patient with two lobe combination resections) had positive margin resection, including 1 with wild-type gene and 3 harboring mutated EGFR (Table 4).

Discussion
With recent advances in diagnostic techniques for lung cancer, detection rate is increasingly higher, and more and more resectable lung adenocarcinomas are found in early stage. In this study, postoperative patients with p-stage I and EGFR mutation accounted for 54.7% \( (p = 0.000) \), followed by p-stage IIIA (28.1%, 18/64), and p-stage II (17.2%, 11/64). In addition, wedge resection, pulmonary segmentectomy and lobectomy were increasingly used, while invasion of peripheral structure by early

| Table 1 | Relationship between local invasion and gene mutation status |
|-----------------------------------|------------------|------------------|------------------|------------------|
| Metastasis                        | Mutated N = 64   | Wild-type N = 39 | \( P \) value (mutated vs. wild-type) |
|-----------------------------------|------------------|------------------|------------------|------------------|
|                                   | Exon 18 N = 2    | exon 19 N = 36   | exon 21 N = 26   |                  |
| Pleural invasion                  | 1                | 22               | 20               | 17               | \( p = 0.018 \)  |
| Lymph node metastasis             | 0                | 12               | 10               | 10               | \( p > 0.05 \)   |
| Endobronchial metastasis          | 1                | 16               | 8                | 7                | \( p = 0.005 \)  |

| Table 2 | Amounts of grades 2 or 3 bronchus invasion |
|---------|-------------------------------------------|
| Diameter| Total Endobronchial metastasis (grades 2 or 3 bronchus) | No endobronchial metastasis (grades 2 or 3 bronchus) |
|---------|----------------------------------------------------------|----------------------------------------------------------|
| <2 cm   | 31                                                        | 5                                                         | 26                                                         |
| 2.1–3 cm| 28                                                        | 7                                                         | 21                                                         |
| 3.1–5 cm| 26                                                        | 10                                                        | 16                                                         |
| 5.1–7 cm| 10                                                        | 7                                                         | 3                                                          |
| >7.1 cm | 8                                                         | 3                                                         | 5                                                          |
lung adenocarcinoma affects postoperative recurrence or treatment [3].

Common local metastases of peripheral lung adenocarcinoma include pleural, endobronchial and lymphatic metastases. Chest CT can be used to assess lymph node enlargement and tumor diameter, but is not sensitive enough to differentiate bronchial mucous membrane and visceral pleural invasion. Postoperative specimens are used to determine pleural and lymph node invasions, but cannot help identify endobronchial metastasis. Since early lung adenocarcinoma can expand along the bronchus [4], bronchoscopy can accurately assess endobronchial metastasis; however, the traditional endoscopic examination aims mainly to obtain pathological diagnosis and does not guide in selecting a surgical procedure for peripheral lung adenocarcinoma in the aspect of endobronchial metastasis [5]. In this study, endobronchial metastasis was defined as grades 2 or 3 invasions in central bronchial anatomic regions in patients with lung adenocarcinoma. Since lobectomy is more difficult in cases with tumor invading lobar bronchus opening or adjacent principal bronchus [6], the sleeved protocol is superior in increasing the length of bronchial incision [7]. When metastatic tumors are observable by bronchoscopy, there may be a high possibility of positive stump after simple lobectomy [8-10]. The recurrence rate after wedge resection is higher than that after pulmonary segmentectomy, while the local recurrence after segmentectomy is more common than when lobectomy is performed [11-15]. Endobronchial metastasis is significantly increased in patients with EGFR mutation, in agreement with our data presented above 39.1 vs 17.9% in patients with mutation and wild-type EGFR, respectively; \( p = 0.005 \). Patients mutated for EGFR might present higher recurrence and decreased 5-year survival rates [16], with better efficacy to chemoradiotherapy after surgery than other types of metastasis [17].

Pleural invasion rate was highest in peripheral lung adenocarcinoma, with patients harboring EGFR mutation showing significantly higher values (62.5%) compared with those without EGFR mutation \( p = 0.018 \). Moreover, recurrence rate after wedge resection was shown to be high in lung adenocarcinoma patients with stage I and pleural invasion [15, 18]. This study

| Table 3 Effects of EGFR mutation on pathological staging |
|---------------------------------|----------------|----------------|----------------|
| p-stage I | p-stage II | p-stage IIIA |
| Mutated  | 35       | 11           | 18            |
| Wild-type| 17       | 13           | 9             |

Fig. 1 CT features and endobronchial metastasis. Endobronchial metastasis in peripheral lung adenocarcinoma. CT scan showing lung cancer in the medial anterior basal segment of left lower lobe, with pleural retraction. Appearance obtained by bronchoscopy. Left lung lower lobe and upper lobe bronchial mucosal hyperemia, infiltration change, and luminal stenosis. Endoscopic biopsy pathology, adenocarcinoma; EGFR mutation, exon 19 deletion mutation.
confirmed a stronger local invasion in patients with EGFR gene mutation, with significantly higher pleural and endobronchial metastases compared with patients without mutation. Furthermore, pleural and endobronchial metastases were significantly more common than lymph node metastasis. Invasion of local structure in early lung adenocarcinoma was to a certain extent associated with postoperative recurrence, which can help provide a basis for surgical treatment. Since p-stage I lung adenocarcinoma incidence is significantly increased in patients with EGFR mutation, it is critical to select an appropriate surgical procedure, especially that with significant effects on the incision margin and recurrence.

Sole TNM staging is unable to predict early lung adenocarcinoma invasion, unlikely to identify recurrence in patients after surgical resection [19, 20], and unable to predict chemotherapeutic efficacy. The relationship between EGFR mutation and peripheral structure invasion can provide a basis for comprehensive therapy. Indeed, postoperative patients with EGFR mutation show higher efficacy rates to targeted therapy and chemotherapy compared with wild-type patients [21]. Patients harboring EGFR mutation are prone to recurrence in the incision margin [22–24], and have a high metastasis rate [25]; however, they still show higher survival after recurrence [26–28]. For instance, the 5-year survival rate in patients with EGFR mutation was shown to be higher than that of cases without mutation [21], which may be related to drug sensitivity and comprehensive treatment. Therefore, clarifying the clinical characteristics of early lung adenocarcinoma patients with EGFR mutation aims to provide a basis for clinical treatment.

The limitation of this study lies in that only patients with operable lung adenocarcinoma were assessed, not including other types of lung cancer. Therefore, further multi-factor, large sample, and multi-center studies are needed to confirm the association of local structure invasion in early lung adenocarcinoma with EGFR.

**Conclusions**

Compared with early resectable lung adenocarcinoma patients harboring wild-type EGFR, those with EGFR mutation showed a higher rate of local invasion, with pleural invasion most common. In addition, endobronchial metastasis incidence was higher than that of lymph node metastasis, suggesting the influence of EGFR mutation on resection scope.

---

**Table 4** Relationship between the surgical method and EGFR

| EGFR      | Lobectomy | Segmentectomy | Wedge resection | Sleeved lobectomy | Two lobe combination resection |
|-----------|-----------|---------------|-----------------|------------------|-------------------------------|
| Mutate-type | 54        | 1             | 4               | 2                | 3                             |
| Wild-type  | 31        | 2             | 4               | 1                | 1                             |

---

**Abbreviations**

EGFR: Epidermal growth factor receptor

**Acknowledgements**

Not applicable.

**Funding**

Project of Medical and Health Science Technology in Shandong Province (2015WS0376).

**Availability of data and materials**

None.

**Authors’ contributions**

YN, WG carried out the molecular genetic studies, participated in the sequence alignment, and drafted the manuscript. WC, HW, CL carried out the immunologicals. HZ, PH participated in the sequence alignment. YZ, XL participated in the design of the study and performed the statistical analysis. XX, HL conceived the study and participated in its design and coordination and helped to draft the manuscript. All authors read and approved the final manuscript.

**Competing interests**

The authors declare that they have no competing interests.

**Ethics approval and consent to participate**

This study was approved by the Medical Ethics Committee of Linyi People’s Hospital, Shandong, China.

**Funding**

None.

**Availability of data and materials**

Not applicable.

**Acknowledgements**

This study was approved by the Medical Ethics Committee of Linyi People’s Hospital, Shandong, China.

**Author details**

1Department of Respiratory Medicine, Linyi People’s Hospital, Linyi 276000, China. 2Department of Blood Screening Test, Linyi People’s Hospital, Linyi 276000, China. 3Department of Oncology, Linyi People’s Hospital, Linyi 276000, China. 4Department of Pathology, Linyi People’s Hospital, Linyi 276000, China. 5Department of Medicine, Linyi People’s Hospital, Linyi 276000, China.

**Received**: 16 May 2016 **Accepted**: 13 January 2017

**Published online**: 03 March 2017

**References**

1. Rusch VW, Asamura H, Watanabe H, et al. The IASLC lung cancer staging project: a proposal for a new international lymph node map in the forthcoming seventh edition of the TNM classification for lung cancer. J Thorac Oncol. 2009;4:568–77.
2. Goto K, Satouchi M, Ishii G, et al. An evaluation study of EGFR mutation tests utilized for non-small-cell lung cancer in the diagnostic setting. Ann Oncol. 2012;23:2914–9.
3. Tomaszek SC, Kim Y, Cassivi SD, et al. Bronchial resection margin length and clinical outcome in non-small cell lung cancer. Eur J Cardiothorac Surg. 2011;40:1151–6.
4. Rabahi MF, Ferreira AA, Reciputti BP, et al. Fiberoptic bronchoscopy findings in patients diagnosed with lung cancer. J Bras Pneumol. 2012;38:445–51.
5. Griffin JP, Zaman MK, Niell HB, et al. Diagnosis of lung cancer: a bronchoscopist’s perspective. J Bronchol. Interv Pulmonol. 2012;19:12–8.
6. Sienel W, Kreschbaum A, et al. Frequency of local recurrence following segmentectomy of stage IA non-small cell lung cancer is influenced by segment localization and width of resection margins—implications for patient selection for segmentectomy. Eur J Cardiothorac Surg. 2007;31:522–7. discussion 7–8.
7. Berthet JP, Paradela M, Jimenez MJ, et al. Extended sleeve lobectomy: one more step toward avoiding pneumonectomy in centrally located lung cancer. Ann Thorac Surg. 2013;96:1988–97.

8. Hofmann HS, Taeger C, Lautenschlager C, et al. Microscopic (R1) and macroscopic (R2) residual disease in patients with resected non-small cell lung cancer. Eur J Cardiothorac Surg. 2002;21:605–10.

9. Riquet M, Achour K, Foucault C, et al. Microscopic residual disease after resection for lung cancer: a multifaceted but poor factor of prognosis. Ann Thorac Surg. 2010;89:870–5.

10. Horinouchi H, Nomori H, Nakayama T, et al. How many pathological T1N0M0 non-small cell lung cancers can be completely resected in one segment? Special reference to high-resolution computed tomography findings. Surg Today. 2011;41:1062–6.

11. Saynak M, Veeramancheni NK, Hubbs JL, et al. Local failure after complete resection of N0-1 non-small cell lung cancer. Lung Cancer. 2011;71:156–65.

12. Okada M, Nishio W, Sakamoto T, et al. Effect of tumor size on prognosis in patients with non-small cell lung cancer: the role of segmentectomy as a type of lesser resection. J Thorac Cardiovasc Surg. 2005;129:87–93.

13. El-Sherif A, Fernando HC, Santos R, et al. Margin and local recurrence after sublobar resection of non-small cell lung cancer. Ann Surg Oncol. 2007;14:2400–5.

14. Canizares MA, Matilla JM, Cueto A, et al. Atypical carcinoid tumours of the lung: prognostic factors and patterns of recurrence. Thorax. 2014;69:648–53.

15. Kolke T, Kolke T, Yoshiya K, et al. Risk factor analysis of locoregional recurrence after sublobar resection in patients with clinical stage IA non-small cell lung cancer. J Thorac Cardiovasc Surg. 2013;146:372–8.

16. Collaud S, Bongiovanni M, Pache JC, et al. Survival according to the site of bronchial microscopic residual disease after lung resection for non-small cell lung cancer. J Thorac Cardiovasc Surg. 2009;137:622–6.

17. Riquet M, Lang-Lazdunski L, Le PB, et al. Characteristics and prognosis of resected T3 non-small cell lung cancer. Ann Thorac Surg. 2002;73:253–8.

18. Smits AJ, Kummer JA, Hinrichs JW, et al. EGFR and KRAS mutations in lung carcinomas in the Dutch population: increased EGFR mutation frequency in malignant pleural effusion of lung adenocarcinoma. Cell Oncol (Dordr). 2012;35:189–96.

19. Iyoda A, Hiroshima K, Moriya Y, et al. Predictors of postoperative survival in patients with locally advanced non-small cell lung carcinoma. Surg Today. 2010;40:725–8.

20. Yano T, Morodomi Y, Ito K, et al. Verification of the newly proposed T category (seventh edition of the tumor, node, and metastasis classification) from a clinicopathological viewpoint in non-small cell lung cancer-special reference to tumor size. J Thorac Oncol. 2010;5:45–8.

21. Deng LL, Deng HB, Lu CL, et al. Mutations of EGFR or KRAS and expression of chemotherapy-related genes based on small biopsy samples in stage IIIIB and IV inoperable non-small cell lung cancer. J Cancer Res Clin Oncol. 2014;140:2097–105.

22. Koh Y, Jang B, Jeon YK, et al. EGFR gene copy number gain is related to high tumor SUV and frequent relapse after adjuvant chemotherapy in resected lung adenocarcinoma. Jpn J Clin Oncol. 2011;41:548–54.

23. Masasyesva BG, Tong BC, Brock MV, et al. Molecular margin analysis predicts local recurrence after sublobar resection of lung cancer. Int J Cancer. 2005;113:1022–5.

24. Ahn HK, Choi YL, Han JH, et al. Epidermal growth factor receptor mutation and treatment outcome of mediastinoscopic N2 positive non-small cell lung cancer patients treated with neoadjuvant chemoradiotherapy followed by surgery. Lung Cancer. 2013;79:900–6.

25. Chen C, Bao F, Zheng H, et al. Local extension at the hilum region is associated with worse long-term survival in stage I non-small cell lung cancers. Ann Thorac Surg. 2012;93:389–96.

26. Zaric B, Stojic V, Kovacevic T, et al. Clinical characteristics, tumor, node, metastasis status, and mutation rate in domain of epidermal growth factor receptor gene in serbain patients with lung adenocarcinoma. J Thorac Oncol. 2014;9:1406–10.

27. Saisho S, Yasuda K, Maeda A, et al. Post-recurrence survival of patients with non-small-cell lung cancer after curative resection with or without induction/adjuvant chemotherapy. Interact Cardiovasc Thorac Surg. 2013;16:166–72.

28. Sonobe M, Kobayashi M, Ishikawa M, et al. Impact of KRAS and EGFR gene mutations on recurrence and survival in patients with surgically resected lung adenocarcinomas. Ann Surg Oncol. 2012;19 Suppl 3:S347–S4.